Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial - Reuters
Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPR0hId1RlLVEwR1pIdkEtOVA2QklyZ0l5TE1INUJKR3plRklPLXZFVXNBdkpWSGc1bm92QVF4NWJMR2QxUHlhUUlGdGk1NHN3Q3RpVHdSZ084YkhhRnlMRTVaZFBaWDF2dTJDZkZaOHZVNXdQaXc5bGZDc2d2bTVvNFBNUXEzQjJWcE9hRlRqamtuTE1leUxBdFBMaDhWUE5IR1cyR0hta0VsN2RMWVNlS291ZmRISElfMjNLSVVxdC0?oc=5" target="_blank">Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026 at 03:45 PMNovartis defeats UK court bid to invalidate blockbuster drug Entresto patent - Reuters
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent Reuters
August 13, 2026 at 09:31 PMNovo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026 at 03:26 PMCapricor shares skyrocket as FDA agrees to review new Duchenne drug data - Reuters
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data Reuters
August 14, 2026 at 10:41 AMUS FDA approves Regeneron's rare bone disorder drug - Reuters
US FDA approves Regeneron's rare bone disorder drug Reuters
August 19, 2026 at 06:53 PMNovo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Novo CEO says obesity market won't be winner-take-all battle with Lilly reuters.com
August 13, 2026 at 10:02 AM